You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Bone targeted antimicrobials for biofilm-mediated osteolytic infection treatment

    SBC: BIOVINC, LLC            Topic: NIDCR

    DESCRIPTION provided by applicant Infectious bone disease is a major cause of morbidity and mortality worldwide Successful treatment often requires surgical intervention with longer term antibiotic therapy Bacterial biofilm pathogens are associated with most osseous infections and represent a major target of therapy The biofilm pathogens associated with chronic bone infections bind to and co ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Preclinical Testing of a Novel Flow Diverting Stent for Treating Intracranial Aneurysms

    SBC: NeuroSigma, Inc.            Topic: 101

    DESCRIPTIONprovided by applicantThe purpose of this project is to develop an improvedminimally invasive treatment for intracranial aneurysmsIntracranial aneurysms are spherical outpouchings of blood vessels in the head that result from weakness in the vessel wallUnruptured aneurysms are present in approximatelyof the general populationand rupture can be devastating with a high morbidity and mortal ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Discovery of Oligodendrocyte Stimulators

    SBC: Medosome Biotec, LLC            Topic: 101

    DESCRIPTION provided by applicant Up to of low birth weight preterm infants manifest some form of periventricular white matter injury PWMI making it the most common form of brain injury affecting premature infants In the US infants per year are born at risk for PWMI and about children per year will develop PWMI World wide infants will be born each year at ri ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  4. Assessment of the glucagon receptor blocker REMD-477 on insulin requirements in type 1 diabetes

    SBC: REMD BIOTHERAPEUTICS INC.            Topic: NIDDK

    DESCRIPTION provided by applicant Fast Track Insulin remains the primary and often the only treatment for type diabetes mellitus T D However it is associated with chronic iatrogenic hyperinsulinemia secondary hyperlipidemia higher incidence and severity of cardiovascular complications and life threatening hypoglycemia events A higher mortality vs due to cardiovascular ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Utilization of cord blood-expanded stem cells for megakaryocyte and platelet production

    SBC: AllCells, LLC            Topic: NHLBI

    DESCRIPTION provided by applicant Platelet transfusions are the most effective treatments for patients with thrombocytopenia The growing demand for platelet transfusions is often limited by shortage in the platelets PTL supply due to dependency on volunteer donors short shelf life risk of infections and alloimmunization It is therefore critical to create an efficient donor independent ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  6. Investigation of a nanoparticle albumin-bound mTOR inhibitor, nab-rapamycin for t

    SBC: AADI, LLC            Topic: 102

    DESCRIPTION provided by applicant In it is estimated that there will be new bladder cancer cases in the United States resulting in deaths Most cases present with nonmuscle invasive bladder cancer NMIBC Intravesical bacillus Calmette Guerin BCG which elicits a nonspecific local immune response is considered the standard first line treatment However ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  7. Development of a Gene and Oligonucleotide Delivery System

    SBC: Molecular Express Inc            Topic: NCATS

    DESCRIPTION provided by applicant The knockdown of targeted genes by anti sense oligonucleotides ODNS and genetic medicines collectively G MEDS holds promise for a variety of therapies The delivery of effective quantities of ODNS to specific cells however has proved to be challenging We propose here a novel approach to ODN delivery that involves enveloped virus like particles EVLPs ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  8. Recyclable Magnetic Co C Hybrid ROMP Reagents Scavengers and Ligands

    SBC: MATERIA, INC.            Topic: 300

    DESCRIPTION provided by applicant This Fast Track Small Business Technology Transfer study between Materia Inc in Pasadena CA and the University of Kansas intends to build upon successes of our current Phase II Fast Track STTR grant R GM which ends on March Preliminary results serve as a solid foundation for this Fast Track submission entitled andquot Development of Re ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  9. Dysbiotic Rebalancing with S. epidermidis Fermentation in Acne Vulgaris

    SBC: Surface Bioadvances, Inc.            Topic: NIAMS

    DESCRIPTION provided by applicant Dysbiosis refers to a condition with microbial imbalances within the human microbiome Yogurts are the best examples of using fermenting gut bacteria to rebalance the gut dysbiosis Our results demonstrate for the first time that Staphylococcus epidermidis S epidermidis a commensal bacterium of the human skin functions as a probiotic microorganism that em ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  10. Novel Activin A Antagonists for Treatment of Osteoporosis

    SBC: ABREOS BIOSCIENCES, INC.            Topic: NIAMS

    DESCRIPTION provided by applicant Bone loss and fragility from osteoporosis afflict more than million people worldwide including at least million Americans Current osteoporosis treatments are significantly deficient most fail to reverse bone loss and or have adverse effects that prohibit their long term use New therapeutic approaches are urgently needed Recently the TGF family li ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government